NSDHL

Across TCGA pan-cancer cohorts, NSDHL Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NSDHL data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher NSDHL Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated NSDHL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUAD, and PRAD are the cancer types where NSDHL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.614	.003	34	view →
LUAD	OS	Median	III,IV	0.153	0.663	.004	18	view →
PRAD	OS	Median	All	0.265	0.884	<.001	4	view →
BRCA	DFS	Median	All	0.647	0.902	.005	4	view →
COAD	DFS	Median	II,III,IV	0.220	0.779	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NSDHL–UCEC (DFS)

Open the UCEC breakdown →